This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2011 Nov 1;29(31):4207; author reply 4207-8.

doi: 10.1200/JCO.2011.37.0536. Epub 2011 Sep 19.

Survival benefit from up-front fluorouracil, leucovorin, and irinotecan/cetuximab in metastatic colorectal cancer: is it just a now-or-never result?

PMID: 21931017
DOI: 10.1200/JCO.2011.37.0536

Comment

Survival benefit from up-front fluorouracil, leucovorin, and irinotecan/cetuximab in metastatic colorectal cancer: is it just a now-or-never result?

Mark J Rother. J Clin Oncol. 2011.

. 2011 Nov 1;29(31):4207; author reply 4207-8.

doi: 10.1200/JCO.2011.37.0536. Epub 2011 Sep 19.

Author

PMID: 21931017
DOI: 10.1200/JCO.2011.37.0536

No abstract available

PubMed Disclaimer

Comment on

Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F. Van Cutsem E, et al. J Clin Oncol. 2011 May 20;29(15):2011-9. doi: 10.1200/JCO.2010.33.5091. Epub 2011 Apr 18. J Clin Oncol. 2011. PMID: 21502544 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Atypon
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information